TRIAL DETAIL

Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Advanced or Metastatic Solid Tumors

Drug:
Trial Name:
Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Advanced or Metastatic Solid Tumors
NCT#:
Conditions:
Solid Tumors
Status:
Ongoing, but not recruiting
Phase:
1
Start Date 04/01/2008
Age of Trial (yrs) 13.7
Treatment Phase:
Gleevec-resistant
Drug Category:
IGF1R inhibitor
Strategy:
Block related tumor signal paths
Trial Type:
GIST not specified. GIST patient enrollment unknown.
Other Protocol IDs:
CA191-002
Sponsor:
Bristol-Myers Squibb
Patient Contact:
For site information outside the USA please email: Clinical.Trials@bms.com First line of email MUST contain NCT# & Site#.
Contact email:
Contact Phone:
Randomized:
IV or Oral:
Oral
Trial Notes:
This is a Phase 1 dose escalation study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of BMS-754807 in patients with advanced or metastatic solid tumors. In addition, the study is expected to identify the recommended dose or dose range of BMS-754807 for Phase 2 studies.

Trial Links

Trial Results

Drug Information

Trial Sites

Name
Address
City
State
Zip
Country
East Melbourne
Victoria
Australia
Heidelberg
Victoria
3084
Australia
Parkville
Victoria
3050
Australia
Footscray
Victoria
3011
Australia